Significant Ownership of Octagon Capital Advisors LP

Signature - Title
/s/ Ting Jia - Managing Member
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Octagon Capital Advisors LP.

Notify me when Octagon Capital Advisors LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Octagon Capital Advisors LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
DTIL Precision BioSciences, Inc. Common Stock, $0.000005 par value 10% $9,570,073 2,328,485 Octagon Capital Advisors LP 31 Dec 2025
GOSS Gossamer Bio, Inc. Common Stock, $0.0001 par value 6.5% $46,938,418 -$13,747,350 15,141,425 -23% Octagon Capital Advisors LP 31 Dec 2025
PALI Palisade Bio, Inc. Common Stock, $0.01 par value 6.4% $18,370,364 9,567,898 Octagon Capital Advisors LP 31 Dec 2025
DNTH Dianthus Therapeutics, Inc. /DE/ Common Stock, $0.001 par value 6.1% $95,095,846 +$12,060,775 2,416,667 +15% Octagon Capital Advisors LP 30 Sep 2025
CRBP Corbus Pharmaceuticals Holdings, Inc. Common Stock, $0.0001 par value 5.4% $7,582,700 955,000 Octagon Capital Advisors LP 31 Dec 2025
AVBP ArriVent BioPharma, Inc. Common Stock, $0.0001 par value 4.9% $36,365,946 1,971,054 Octagon Capital Advisors LP 30 Sep 2025
UNCY Unicycive Therapeutics, Inc. Common Stock, $0.001 par value 4.7% $5,870,000 1,000,000 0% Octagon Capital Advisors LP 31 Dec 2025
TSHA Taysha Gene Therapies, Inc. Common Stock, $0.00001 par value 3.3% $29,650,725 -$4,520,775 9,067,500 -13% Octagon Capital Advisors LP 30 Sep 2025

Schedules 13D/G Reported by Octagon Capital Advisors LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.